AstraZeneca: secures supply capacity for Covid-19 vaccine

(CercleFinance.com) - AstraZeneca said that it has reached a 750 million dollar agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) and Gavi the Vaccine Alliance, two non-profit making organisations, to support the manufacture of 300 million doses of Oxford University's Covid-19 vaccine, with delivery starting by the end of the year.


The drugmaker said it also reached a licensing agreement with the Serum Institute of Indiato to supply one billion doses to low and middle-income countries, with a commitment to provide 400 million does by the end of 2020.

"We are working (...) to honour our commitment to ensure broad and equitable access to Oxford's vaccine across the globe and at no profit," Pascal Soriot, AstraZeneca's CEO said.

AstraZeneca recently agreed to supply 400 million doses to the US and UK after reaching a licence agreement with Oxford University for its vaccine project, known as AZD1222.

Oxford University recently announced the start of a Phase II/III trial of AZD1222 in about 10,000 adult volunteers.

Copyright (c) 2020 CercleFinance.com. All rights reserved.